• Friday, 4 September
  • Saturday, 5 September
  • Sunday, 6 September
General Session
State-of-the-Art Lecture
Symposium
Special Lecture
Industry Symposium
Workshop
TIME
08:30
11:15
Registration
08:00
11:00
Focused Pre-Meeting Workshops

09:00
11:00
11:15
11:30
Opening Ceremony
Jordi Bruix, MD (Spain); Josep M Llovet, MD (USA/Spain); Peter Galle, MD (Germany); ILCA Governing Board
11:30
13:00
General Session 1: Genomics and signalling pathways
Chairs: Marco Pierotti, PhD (Italy) and Peter Galle, MD (Germany)O-001 Sorafenib inhibits IL-6 induced STAT3 signaling by induction of phosphatase SHP2 in cholangiocarcinoma
Boris R. A. Blechacz3, Rory L. Smoot3, Steven F. Bronk3, Nathan W. Werneburg3, Scott M. Wilhelm1, Alphonse E. Sirica2, Gregory J. Gores*3
1, Bayer HealthCare Pharmaceuticals, Montville, 2, Virginia Commonwealth University School of Medicine, Richmond, 3Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, United StatesO-002 Immune cell-related MICRORNA-155 is associated with human liver cirrhosis and hepatocellular carcinoma
Anuradha Budhu*1, Zhipeng Yu1, Marshonna Forgues1, Zhao-You Tang2, Carlo M. Croce3, Xin W. Wang1
1Laboratory of Human Carcinogenesis, National Institutes of Health, Bethesda, United States, 2Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, 3Comprehensive Cancer Center, Ohio State University, Ohio, United StatesO-003 MICRORNA (miRNA) expression profiles define a new molecular subclass of hepatocellular carcinoma
Sara Toffanin*1, Anja Lachenmayer1, Yujin Hoshida2, Laia Cabellos1, Jun Lu2, Augusto Villanueva3, Derek Y. Chiang2, Beatriz Minguez1, Radoslav Savic1, Sasan Roayaie1, Jordi Bruix3, Myron E. Schwartz1, Vincenzo Mazzaferro4, Samuel Waxman1, Scott L. Friedman1, Todd R. Golub2, Josep M. Llovet1
1Mount Sinai Liver Cancer Programme, Division of Liver Diseases, Hemato-Oncology and Surgical Oncology, Mount Sinai School of Medicine, New York, 2Cancer Programme, Broad Institute of Harvard and MIT, Cambridge, MA, United States, 3Barcelona-Clinic Liver Cancer Group (BCLC), Liver Unit, CIBERehd, Hospital Clinic, Barcelona, Spain, 4Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, ItalyO-004 Cancer pathway profiling in experimental tumors derived from immortalised human hepatocytes with aberrant wnt/beta-catenin activation
Henning Wege*1, Denise Heim1, Ansgar W. Lohse1, Tim H. Bruemmendorf2
1Department of Gastroenterology and Hepatology, 2Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

O-005 c-Met is required for stem cell-mediated liver regeneration
Valentina M. Factor
*1, Tsuyoshi Ishikawa1, Jens U. Marquardt1, Chiara Raggi1, Elizabeth A. Conner1, Snorri S. Thorgeirsson1
1Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, United States

O-006 Kupffer cell suppression of intratumoral T cell effector responses is mediated by B7-H1 and PD-1 interactions in human hepatocellular carcinoma (HCC)
Theodore H. Welling*1, Ke Wu1, Ilona Kryczek1, Jorge A. Marrero2, Weiping Zou1
1Surgery, 2Internal Medicine, University of Michigan Health System, Ann Arbor, United States

13:00
13:15
Session Break
13:15
14:15
Bayer Symposium: Setting New Standards in HCC: From Diagnosis to Treatment
Chair: Jordi Bruix, MD (Spain)

  • style=”color:#ffffff;”Introduction
    Jordi Bruix, MD (Spain)
  • Why Hepatocyte Specific Imaging in Liver Diagnosis?
    Jens Ricke, MD (Germany)
  • Recurrent HCC After Curative Treatments: Adjuvant Strategies to Address an Unmet Need
    Vincenzo Mazzaferro, MD (Italy)
  • Best Practices and Treatment Options in Intermediate-stage HCC in the Era of Systemic Therapy
    Riccardo Lencioni, MD (Italy)
  • Future Prospects on Molecular Targeted Therapies in HCC
    Josep M Llovet, MD (USA/Spain)
  • Panel Discussion and Audience Q&A
    Jordi Bruix, MD (Spain)
  • Closing Remarks and Conclusions
    Jordi Bruix, MD (Spain)
14:15
15:00
State of the Art Basic Lecture: Molecular drivers of benign liver tumors
Introduction and perspective: Snorri Thorgeirsson, MD, PhD (USA)
Speaker: Jessica Zucman-Rossi, MD, PhD (France)
15:00
17:00
ILCA Symposium 1: Hepatocellular carcinoma: identifying targets for novel therapies
Chairs: Josep M Llovet, MD (USA/Spain) and Eric Raymond, MD (France)

  • Experimental data with pipeline drugs in HCC
    Jean Francois Dufour, MD (Switzerland)
  • Linking signalling pathways and molecular therapies in HCC
    Josep M Llovet, MD (USA/Spain)
  • Biomarkers and imaging end-points with targeted therapies
    Andrew Zhu, MD (USA)
  • Comparing results with targeted therapies: HCC vs. other cancers
    Sandrine Faivre, MD (France)
17:00
17:30
Coffee and Networking Break
17:30
19:00
General Session 2: Biomarkers and novel targets
Chairs:Didier Samuel, MD (France) and Ronnie Poon, MD (China)O-007 Glucose intolerance is an independent risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C
Hirokazu Takahashi*1, Toshihiko Mizuta1, Takuya Kuwashiro1, Satoshi Ooeda1, Noriko Ooza1, Hiroshi Hamajima1, Yasunori Kawaguchi1, Yuichirou Eguchi1, Iwata Ozaki1, Kazuma Fujimoto1
1Internal Medicine, Saga University, Saga, Japan O-008 Optimisation of CT imaging protocols for characterising small (1-2 cm) nodules in HCC surveillance population
Hyun-Jung Jang*1, Korosh Khalili1, Masoom Haider1, Seong Ho Park2, Tae Kyoung Kim1
1Medical Imaging, University of Toronto, Toronto, Canada, 2Radiology, Asan Medical Center, Seoul, South KoreaO-009 Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
Zhen Fan Yang*1, Sheung Tat Fan1, David W. Y. Ho1, Wan Ching Yu1, Chi Keung Lau1, Michael N. P. Ng1, Chun Yip Lam1
1Department of Surgery, The University of Hong Kong, Hong Kong, ChinaO-010 High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma
Yang Xu
*1, Xinrong Yang1, Jia Fan1
1Liver cancer institute, Zhongshan Hospital,Fudan University, Shanghai, China

O-011 The novel pan-deacetylase inhibitor panobinostat induces alternative pathways of apoptosis in hepatocellular carcinoma models
Pietro Di Fazio1, Karl Quint1, Abbas Agaimy2, Claudia Steindorf1, Regine Schneider-Stock2, Daniel Neureiter3, Matthias Ocker*1
1Medicine 1, 2Pathology, University Hospital Erlangen, Erlangen, Germany, 3Pathology, Paracelsus Private Medical University, Salzburg, Austria

O-012 Genomic and epigenetic based prediction of response to zebularine therapy in human liver cancer
Jesper B. Andersen
*1, Chiara Raggi1, Jens U. Marquardt1, Elisabeth A. Conner1, Yun-Han Lee1, Valentina M. Factor1, Snorri S. Thorgeirsson1
1Laboratory of Experimental Carcinogenesis, National Cancer Institute NIH, Bethesda, United States

19:00 Welcome Reception / Social Event
TIME Saturday, 5 September
07:30 – 08:30 Early Morning Workshops

New trends in interventional oncology for liver tumours
Chairs: Riccardo Lencioni, MD (Italy) and Riad Salem, MD (USA)
Guidelines for research and management of HCC
Chairs: Morris Sherman, MD (Canada) and Andrew Zhu, MD (USA)
Liver Transplantation for Rare Tumors in Adult Recipients
Chairs: Pierre-Alain Clavien, MD (Switzerland) and Vincenzo Mazzaferro, MD (Italy)
Apoptotic and interleukin pathways in HCC
Chairs: Lewis Roberts, PhD (USA) and Jesus Prieto, MD (Spain)
08:30 – 09:00 Special Lecture 1: Systemic regulation of HCC cancer development and progression
Speaker: Jianren Gu, PhD (P.R. China)
09.00 – 10.30 General Session 3: Curative therapies
Chairs: Kim Olthoff, MD (USA) and Pietro Majno, MD (Switzerland)

O-013 Characterisation of small (1-2 cm) hepatic nodules in HCC screening population: analysis of multiple imaging parameters of Gd-BOPTA-enhanced MR imaging  
Tae Kyoung Kim
*1, Korosh Khalili1, Masoom Haider1, Seong Ho Park2, Hyun-Jung Jang1
1Medical Imaging, University of Toronto, Toronto, Canada, 2Radiology, Asan Medical Center, Seoul, South Korea

O-014 Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan and UCSF criteria  
Carole Macaron
*1, Ibrahim A. Hanouneh1, Federico Aucejo2, Rocio Lopez3, Nizar N. Zein4
1Internal Medicine, 2General Surgery, Transplant Center, 3Quantitative Health Sciences, 4Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, United States

O-015 Predictors of mortality among patients with perihilar cholangiocarcinoma  
William Sanchez
*1, Joseph Kaiya2, Lewis R. Roberts2, Gregory J. Gores2
1Miles and Shirley Fiterman Center for Digestive Diseases, 2Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States

O-016 Systematic review of randomised and nonrandomised trials on the clinical efficacy and safety of neoadjuvant transarterial chemoembolisation for resectable hepatocelluar carcinoma  
Terence C. Chua*1, Winston Liauw2, Akshat Saxena1, Francis Chu1, Derek Glenn3, Alan Chai3, David L. Morris1
1Department of Surgery, 2Department of Medical Oncology, 3Department of Radiology, St George Hospital, Sydney, Australia

O-017 Long-term results of liver transplantation for hepatocellular carcinoma in 15 HIV+ patients 
Eric Vibert*1, Jean-Charles Duclos-Vallee2, Maria Rosa Ghigna3, Catherine Guettier3, Daniel Azoulay1, Denis Castaing1, Didier Samuel4, Rene Adam1
1Centre Hepato-Biliaire, AP-HP Hopital Paul Brousse, 2U 785, INSERM, Villejuif, 3Laboratoire Anatomie Pathologique, AP-HP Hopital de Bicetre, Le Kremlin-Bicetre, 4UMR-S785, Univ Paris-Sud, Villejuif, France

O-018 Clinical characteristics and prognosis of treatment-naive 1,471 patients with hepatocellular carcinoma: 5-year experience of single institute  
Kwang-Hyub Han1, Seung Up Kim*1, Jun Yong Park1, Do Young Kim1, Sang Hoon Ahn1, Chae Yoon Chon1, Jinsil Seong2, Do Youn Lee3, Jong Tae Lee3, Kyung Sik Kim4, Jin Sub Choi4
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, 2Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea, 3Department of Radiology, Yonsei University College of Medicine, Seoul, Korea, 4Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Severance Hospital, Seoul, South Korea

10:30 – 11:00 Coffee and Networking Break
11:00 – 12:30 ILCA Plenary General Session
Chairs: Massimo Colombo, MD (Italy) and Nelson Fausto, MD (USA)

ILCA Report
Josep M Llovet, MD (USA/Spain)

O-019 Signal pathways during HCC pathogenesis: from genomics to mouse models  
Susie Lee1, Coral Ho1, Deigo Calvisi2, Xin Chen*1
1Biopharmaceutical Sciences, UCSF, San Francisco, United States, 2Pathology, University of Greifswald, Greifswald, Germany

O-020 Gene-expression signature predicts development of hepatocellular carcinoma and survival in cirrhotic patients  
Yujin Hoshida
*1, Augusto Villanueva2, Angelo Sangiovanni3, Manel Sole2, Joshua Gould1, Supriya Gupta4, Stacey Gabriel4, Judit Peix2, Massimo Colombo3, Josep M. Llovet2, Todd R. Golub1
1Cancer Programme, Broad Institute, Cambridge, United States, 2HCC Translational Research Lab, BCLC-Group, IDIBAPS, CIBERHED, Hospital Clínic, Barcelona, Spain, 3Department of Gastroenterology and Endocrinology, A.M. & A. Migliavacca Center for Liver Disease, FIRC Unit on Liver Cancer, IRCCS Maggiore Hospital a, Milan, Italy, 4Genetic Analysis Platform, Broad Institute, Cambridge, United States

O-021 Integrating genomic and transcriptional aberrations in hepatoblastoma
Carolina Armengol
*1, Emilie Thomas2, Stefano Cairo3, Aurélien de Reyniès2, Monique Fabre4, Marie Annick Buendia3
1Hepatology Unit, Health Science Research Institute. Germans Trias i Pujol Foundation. CIBERehd, Badalona, Spain, 2Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, 3Oncogenesis and Molecular Virology Unit, Institut Pasteur. INSERM U579, 4Service d’Anatomie et de Cytologie Pathologiques, Université Paris-Sud 11, APHP Hôpital de Bicêtre, Paris, France

O-022 Pegintron maintenance therapy in cirrhotic (metavir F4) HCV patients who failed to respond to interferon/ribavirin (IR) therapy: final results of the EPIC3 cirrhosis maintenance trial  
J Bruix
*1, T Poynard2, M Colombo3, E Schiff4, J Reichen5, K Burak6, E Heathcote7, T Berg8, J Poo-Ramirez9, C Brandao Mello10, R Guenther11, C Niederau12, R Terg13, N Boparai14, J Harvey14, L Griffel14, M Burroughs14, C Brass14, J Albrecht14
1, U Barcelona, Barcelona, Spain, 2, Hopital La Petie Salpetriere, Paris, France, 3, Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy, 4, U Miami, Miami, United States, 5, U Bern, Bern, Switzerland, 6, U Calgary, Calgary, 7, Toronto Western Hosp, Toronto, Canada, 8, Charite Campus Virchow Klinikum, Berlin, Germany, 9, Hosp Medica Sur, Mexico City, Mexico, 10, Hosp U Gaffree Guinle, Rio de Janeiro, Brazil, 11, U Schleswig-Holstein, Kiel, 12, St Josef Hosp, Oberhausen, Germany, 13, Hosp Municipal De Gastroenerologia, Buenos Aires, Argentina, 14, Schering-Plough Research Institute, Kenilworth, United States

O-023 Transcatheter arterial chemoembolisation for unresectable hapatocellular carcinoma: a long term outcomes and prognostic factor analysis with 1816 patients  
Zheng-Gang Ren
*1, Jing-Lin Xia1, Yu-Hong Gan1, Ning-Ling Ge1, Yi Chen1, Bo-Heng Zhang1, Yan-Hong Wang1, Sheng-Long Ye1
1Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

12:30 – 13:00 ILCA President’s Farewell Note: Present and future research in HCC
Introduction and perspective: Greg Gores, MD (USA)
Speaker: Jordi Bruix, MD (Spain)
13:15 – 14:15 Novartis Oncology Symposium: Improving Clinical Outcomes: The Emerging Role of
mTOR Inhibition in HCC

Chair: Ronnie Poon, MD (PR China)

• Welcome and Introduction
Ronnie Poon, MD (PR China)
• Retrospective: Current Trends and Unmet Needs in the Management of
Advanced Hepatocellular Carcinoma
Ronnie Poon, MD (PR China)
• mTOR as a Novel Target in Hepatocellular Carcinoma
Jean-Francois Dufour, MD (Switzerland)
• Emerging Clinical Evidence for RAD001 in Advanced Hepatocellular Carcinoma
Li-Tzong Chen, MD, PhD (Taiwan)
• Panel Discussion and Audience Q&A
Ronnie Poon, MD (PR China)
• Closing Remarks and Conclusions
Ronnie Poon, MD (PR China)

Terumo/Biocompatibles Symposium: DC Bead in the Treatment of Hepatocellular Carcinoma:
Where Do We Stand?

Chair: Jordi Bruix, MD (Spain)

• Rationale of PRECISION TACE with Drug-Eluting Bead
Thomas Vogl, MD (Germany)
• Transarterial Chemoembolisation for Hepatocellular Carcinoma: Lessons Learned from Randomised Trials
Riccardo Lencioni, MD (Italy)
• DEB-TACE Versus Conventional TACE for HCC in Patient Awaiting Liver Transplantation: Preliminary Results of a Randomised Trial
Thomas Kröncke, MD (Germany)
• Panel Discussion and Audience Q&A
Jordi Bruix, MD (Spain)
• Closing Remarks and Conclusions
Jordi Bruix, MD (Spain)
14:15 – 15:00 Poster Viewing Session
Chairs: Jordi Bruix, MD (Spain) and Marie Annick Buendia, MD (France)
15:00 – 15:30 Special Lecture 2: Pathogenesis of liver fibrosis: milieu for HCC development
Speaker: Scott Friedman, MD (USA)
15:30 – 16:00 Coffee and Networking Break
16:00 – 17:30 General Session 4: Loco-regional therapies 
Chairs: Michel Beaugrand, MD (France) and Masatoshi Kudo, MD, PhD (Japan)

O-024 Contrast enhanced ultrasound of intrahepatic peripheral cholangiocarcinoma in cirrhotic patients  
Alejandro Forner
*1, Ramon Vilana2, Luis Bianchi2, Ángeles García-Criado2, Jordi Rimola2, Carlos Rodríguez de Lope1, María E. Reig1, Carmen Ayuso2, Concepció Bru2, Jordi Bruix1
1Liver Unit. BCLC group, 2Radiology Department. BCLC group, Hospital Clinic. IDIBAPS. CIBERahd., Barcelona, Spain

O-025 Reduced liver toxicity in intermediate-stage hepatocellular carcinoma patients treated by chemoembolisation with drug eluting bead: results from the PRECISION V randomised trial  
Riccardo Lencioni
*1, Katerina Malagari2, Thomas Vogl3, Frank Pilleul4, Alban Denys5, Anthony Watkinson6, Johannes Lammer7
1Diagnostic Imaging and Intervention, University of Pisa, Pisa, Italy, 2Radiology, University of Athens, Athens, Greece, 3Radiology, University of Frankfurt, Frankfurt, Germany, 4Radiology, Centre Hospitalier Universitaire, Lyon, France, 5Radiology, Centre Hospitalier Universitaire, Lausanne, Switzerland, 6Radiology, Royal Devon and Exeter Hospital, Exeter, United Kingdom, 7Radiology, University of Vienna, Vienna, Austria

O-026 Toxicity of Y90-radioembolisation resulting from radiation of non-target tissues  
Mercedes Iñarrairaegui*1, Delia D’Avola2, José I. Bilbao3, Javier Rodriguez4, Maria M. Rodriguez5, Antonio Martinez De La Cuesta3, Felix Alegre1, José I. Herrero2, Jorge Quiroga2, Jesus Prieto2, Bruno Sangro2
1Liver Unit, 2Liver Unit and CIBERehd, 3Radiology, 4Oncology, 5Nuclear Medicine, Clinica Universitaria, Pamplona, Spain

O-027 Impact of prior surgical resection with curative intent on the efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): subset analysis of the Asia-Pacific (AP) study  
Shukui Qin
*1, Tsai-Sheng Yang2, Won-Young Tak3, Shiying Yu4, Chao-Jung Tsao5, Jun Suk Kim6, Karin Burock7, Jessie Zou8, Dimitris Voliotis9, Ann-Lii Cheng10
1Oncology, Nanjing 81 Hospital, Nanjing, China, 2, Chang Gung Memorial Hospital, Linkou, Taiwan, 3, Kyungpook National University Hospital, Daegu, South Korea, 4, Tongji Hospital, Tongji Medical College, Wuhan, China, 5, Chi Mei Medical Center, Liou Ying Campus, Tainan, Taiwan, 6, Korea University Guro Hospital, Seoul, South Korea, 7, Bayer Schering Pharma, Wuppertal, Germany, 8, Bayer Schering Pharma, Shanghai, China, 9, Bayer HealthCare Pharmaceuticals, Montville, United States, 10, National Taiwan University Hospital, Taipei, Taiwan

O-028 Efficacy of high-dose conformal radiotherapy (CRT) combined to transarterial chemoembolisation (TACE) for single hepatocellular carcinoma (HCC) nodule  
Philippe Merle
*1, Marie Cuinet2, Denis Marion2, Emmanuel Maillard1, Virginie Wautot3, Christian Trepo1, Fabien Zoulim1, Françoise Mornex3
1Hepatology, 2Radiology, Hotel-Dieu, 3Radiotherapy, Lyon Sud, Lyon, France

O-029 Phase II trial of bevacizumab combined with transarterial chemoembolisation (TACE) for hepatocellular carcinoma: initial experience at two institutions  
Diane K. Reyes
*1, Josephina A. Vossen1, Ihab R. Kamel1, Mary F. Mulcahy2, Riad Salem3, Wells Messersmith4, Colin D. Weekes4, Christos S. Georgiades1, Kelvin Hong1, Jean-Francois H. Geschwind1
1Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, 2Department of Hematology / Oncology, 3Department of Radiology, Northwestern University Medical School, Chicago, 4Department of Medical Oncology, University of Colorado Denver, School of Medicine, Denver, United States

17:45 – 18:45 Bracco Symposium: The New Modality – Contrast-Enhanced UltraSound (CEUS) in Liver Imaging
Chairs: Riccardo Lencioni, MD (Italy) and Vincenzo Mazzaferro, MD (Italy)

• What Clinicians Need to Know about Liver Imaging
Vincenzo Mazzaferro, MD (Italy)
• Guidelines on the Use of CEUS Modality for Focal Liver Lesions Imaging
Riccardo Lencioni, MD (Italy)
• Modality in the Management of Nodules in Cirrhosis
Fabio Piscaglia, MD (Italy)
• CEUS – The Real Time Modality for Early Assessment of Liver Tumour Treatment Response
Mohamed Chebil, MD (France)
• Final Discussion and Conclusions

Sirtex Symposium: Improving Outcomes for Patients with Unresectable HCC:
the Role of Radioembolisation

Chair: Luigi Bolondi, PhD (Italy)

• Introduction and Welcome
Luigi Bolondi, PhD (Italy)
• Clinical Outcomes from Sir-Spheres Radioembolisation in Unresectable HCC
Bruno Sangro, PhD (Spain)
• Clinical Trials Using Sir-Spheres, Alone and in Combination with Systemic Therapy
Jens Ricke, PhD (Germany)
• Panel Discussion and Audience Q&A
Luigi Bolondi, PhD (Italy)
• Closing Remarks and Conclusions
Luigi Bolondi, PhD (Italy)
18:45 – 19:15 ILCA Business Meeting
TIME Sunday, 6 September
07:30 – 8:30 Early Morning Workshops

Novel concepts in pre-neoplastic lesions
Chairs: Masamichi Kojiro, MD (Japan) and Tania Roskams, MD (Belgium)
Etiology and pathway activation in HCC
Chairs: Curtis Harris, MD (USA) and Massimo Levrero, MD (Italy)
Future of chemotherapy in liver cancer
Chairs: Eric Raymond, MD (France) and Tim Meyer, MD (UK)
08:30 – 09:00 Special Lecture 4: Progress in liver regeneration and liver cancer research
Speaker: Nelson Fausto, MD (USA)
09:00 – 11:00 ILCA Symposium 2: Cholangiocarcinoma: from genomics to therapy
Chairs: Gregory Gores, MD (USA) and Jessica Zucman-Rossi, MD, PhD (France)

Pathogenesis of cholangiocarcinoma
Gregory Gores, MD (USA)
Surveillance for early detection and diagnosis
Kirsten M. Boberg, MD, PhD (Norway)
Surgical approach for the treatment of cholangiocarcinoma
Pierre-Alain Clavien, MD (Switzerland)
Systemic therapies: what can be tested
Chris Verslype, MD, PhD (Belgium)
11:00 – 11:30 Coffee and Networking Break
11:30- 12:15: State of the Art Clinical Lecture: Epidemiological perspective: HBV vaccinations and implications in HCC development
Introduction and perspective: Morris Sherman, MD (Canada)
Speaker: Ann-Lii Cheng, MD (Taiwan)
12:15 – 13:45 General Session 5: Novel Therapies
Chairs: Ann-Lii Cheng, MD (Taiwan) and Sheng-Long Ye, MD (P.R. China)

O-030 Phase 2 study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC)  
Jean-Luc Raoul*1, Richard S. Finn2, Yoon-Koo Kang3, Joong-Won Park4, Rosemarie Harris5, Vlad Coric5, Christine Baudelet5, Ian Walters5
1Dept d Oncologie Medicale, Centre E Marquis, Rennes, France, 2Geffen School of Medicine, UCLA, Los Angeles, United States, 3University of Ulsan College of Medicine, Asan Medical Center, Seoul, 4, National Cancer Center, Goyang, South Korea, 5, Bristol-Myers Squibb, Princeton, United States

O-031 Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma  
Ahmed O. Kaseb
*1, Michiko Iwasaki1, Milind Javle2, Georgiana Onicescu3, Elizabeth Garrett-Mayer4, James Abbruzzese1, Melanie Thomas4
1GI Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, United States, 2, , 3Department of Biostatistics, 4Medical Oncology, Hollings Cancer Center, Charleston, United States

O-032 Menatetrenone, a vitamin K2 analog, tends to suppress recurrence of hepatocellular carcinoma in patients undergo surgical resection – a randomised prospective study  
Tokihiko Sawada
*1, Masato Kato1, Junji Kita1, Mitsugi Shimoda1, Keiichi Kubota1
1Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan

O-033 Survival of patients treated with Yttrium-90 radioembolisation vs chemoembolisation for unresectable hepatocellular carcinoma  
Laura E. Moreno Luna
*1, William Sanchez2, Andrews C. James3, Gregory A. Wiseman3, Lewis R. Roberts2
1Gastroenterology and Hepatology, mayo clinic, rochester, 2Gastroenterology and Hepatology, 3Radiology, Mayo Clinic, Rochester, United States

O-034 Open-label, multicenter phase 2 trial of ABT-869 in advanced hepatocellular carcinoma (HCC) patients: prognostic factors.  
Wei-Peng Yong
*1, Pei-Jer Chen2, Jennifer Knox3, Sharlene Gill4, Dawn Carlson5, Jiang Qian6, Qin Qin6, Justin Ricker5, Han-Chong Toh7
1Department of Haematology-Oncology, National University Hospital, Singapore, Singapore, 2Division of Digestive Diseases, National Taiwan University Hospital, Taipei, Taiwan, 3Department Medical Oncology, Princess Margaret Hospital, Tornto, 4Department Advanced Therapeutics, British Columbia Cancer Center, Vancouver, Canada, 5Oncology, 6Global Statistics and Data Management, Abbott Laboratories, Abbott Park, United States, 7Department Medical Oncology, National Cancer Centre Singapore, Republic of Singapore

O-035 Inhibition of the TGF-beta1 pathway as a new anti-stromal therapy in hepatocellular carcinoma  
Antonio Mazzocca1, Emilia Fransvea1, Rosa Maritato1, Francesca Baldassarre1, Salvatore Antonaci1, Gianluigi Giannelli*1
1Internal Medicine, Immunology and Infectious Diseases, University of Bari, Medical School, Bari, Italy

13:45 Closing Ceremony